At least one in a thousand pregnancies is complicated by cancer and, as the maternal age at pregnancy increases, numbers are growing. If chemotherapy cannot be postponed, both doctors and patients face complex medical and ethical issues. There is a conflict between optimal maternal therapy and fetal wellbeing. Treatment during the first trimester increases the risk of congenital malformations, spontaneous abortions and fetal death. Second and third trimester exposure is less risky, but it can cause intrauterine growth retardation and low birth weight. Other effects on pregnancy after the first trimester include premature birth, stillbirth, impaired functional development, myocardial toxicity and myelosuppression. Counseling and management of these cases are difficult, because literature is mostly represented by case reports or retrospective series while randomized prospective studies or guidelines are lacking. Moreover, personal experience is often scanty due to the rarity of the condition. This article reviews the available data regarding the different aspects of systemic treatment of cancer during pregnancy to help oncologist and obstetricians in counseling their patients and treat them accordingly.
At least one in a thousand pregnancies is complicated by cancer and, as the maternal age at pregnancy increases, numbers are growing. If chemotherapy cannot be postponed, both doctors and patients face complex medical and ethical issues. There is a conflict between optimal maternal therapy and fetal wellbeing. Treatment during the first trimester increases the risk of congenital malformations, spontaneous abortions and fetal death. Second and third trimester exposure is less risky, but it can cause intrauterine growth retardation and low birth weight. Other effects on pregnancy after the first trimester include premature birth, stillbirth, impaired functional development, myocardial toxicity and myelosuppression. Counseling and management of these cases are difficult, because literature is mostly represented by case reports or retrospective series while randomized prospective studies or guidelines are lacking. Moreover, personal experience is often scanty due to the rarity of the condition. This article reviews the available data regarding the different aspects of systemic treatment of cancer during pregnancy to help oncologist and obstetricians in counseling their patients and treat them accordingly.
Management of pregnant women with cancer using antiblastic chemotherapy (AC) poses unusual medical and ethical challenges. There is frequently a conflict of interest between the mothers and the child, as the most appropriate and timely treatment for the mother can be risky for the fetus. So, the decision to use AC during pregnancy must be weighed against the effects oftreatment delay on maternal survival. Physicians may be reluctant to treat the mother aggressively. The delay or the suboptimal treatment may, however, substantially reduce the mother's chance of surviving the disease (l, 2).
AC during the first trimester may cause severe fetal effects. Thus, when malignancies are diagnosed during the first phases of pregnancy and AC is mandatory, abortion should be considered and proposed. For women who wish to proceed with the pregnancy, the choice of drugs must consider possible embryo-fetal effects. Aggressive chemotherapy regimens increase the obstetric risk, in particular the risk of spontaneous abortion and fetal malformations. Single drug administration might be less risky, but also less effective (3) .
For malignancies diagnosed in the second trimester, the risk of adverse fetal outcome is lower and still the decision is difficult. In case of a chemo sensitive disease it is unwise to delay treatment until after delivery. Nonetheless, preterm labor, intra uterine growth restriction (IUGR), and stillbirth have been described using AC in this part of the pregnancy (4) (5) (6) (7) (8) (9) .
The management of pregnant women with cancer is complicated by the fact that little research is available to guide women and doctors: data are often scarce, antiquated or based on retrospective series and case reports and evidence based guidelines are lacking. The relatively rare occurrence ofpregnancy-associated cancer and the ethical problems precludes conducting large, prospective studies to examine diagnostic, management and outcome issues.
Studies on transplacental transfer of drugs are few and rather contradictory. Even for the most commonly studied agents, e.g. doxorubicin and cisplatin, no consistency has been demonstrated regarding their transplacental passage and detection in products ofconception (10, 11) .Only one study reporting maternal and fetal drug concentrations in primates treated with chemotherapy during pregnancy has been published (12) .
Research on the fetal effects of chemotherapy can also be confounded by the fact that an aggressive and widespread neoplasm can directly affect the pregnancy. The more aggressive the cancer, the more intense the oncological treatment, so it might be difficult to separate the effects of the treatment from those of the neoplasm on the pregnancy course and fetal wellbeing (13, 14) . Hematologic tumors or malignant melanoma can even invade the placenta and pass into the fetal circulation. (6, 15, 16) The embryo-fetal risk can also be influenced by radiotherapy co-treatment. The threshold dose of ionizing radiation below which such treatment is safe for the fetus is impossible to establish. Exposure during the first trimester to a dose as low as 10 cGy appears to increase the risk of fetal abnormalities; exposure to 3 to 5 cGy increases the risk of childhood cancers (17) .
In order to help clinicians to better counsel patients treated with antiblastic chemotherapy (AC) during pregnancy, we reviewed the available literature about obstetrical, fetal and neonatal outcome.
METHODS:
We systematically searched the English literature using MEDLINE and Cochrane Controlled Trials Register databases from 1971 to 2012. Medical Subject Headings terms (cancer, chemotherapy, complications, neoplastic/drug therapy) combined with pregnancy, gestation, pregnancy care, patient education, counseling, and management were used. All titles and abstracts were evaluated excluding letters and editorials. Each article was evaluated to capture any relevant data regarding the counseling of cancer patients candidate or exposed to AC during pregnancy.
ANTIBLASTIC CHEMOTHERAPY PHARMACOLOGY IN PREGNANCY
Pregnancy-associated physiological alterations may modify pharmacokinetics and pharmacodynamics of drugs and appear to lead to decrease plasma levels of antiblastic drugs. In a preclinical and clinical study (18) intraindividual comparative pharmacokinetic data were obtained for doxorubicin and paclitaxel/platinum in pregnant baboons and women. A decreased area under the curve (AVe) and maximal plasma concentration and an increased distribution volume and clearance are observed in pregnancy using AC. Drugs are easily absorbed during pregnancy and albumin binding is lower compared to non-pregnant women. The higher volume of distribution induces, not only lower peak plasma concentration, but also a lower steady state serum concentration, lower plasma half-life, higher clearance rate, and a faster hepatic oxidation. (19) Even though these changes decrease active drug concentrations compared with non-pregnant women who share the same weight, there are no proper studies that justify changes in standard AC dosage in pregnant patients.
In the hope to reduce the negative effects on the fetus lower doses of AC during pregnancy to induce remission, followed by consolidative therapy at standard doses postpartum were proposed (20) , but they might be inadequate to properly cure cancer and thus, full dosages ofAC are recommended during pregnancy. (21-25) AC could adversely affect placental function. As an example, 6-mercaptopurine inhibits both migration and proliferation of trophoblast cells in first-trimester human placental explants culture (26-28) and excessive polyploidization of the chorion leave trophoblast has been described when AC was given in the first trimester (29).
Placental perfusion studies can provide additional valuable information regarding both transfer and biotransformation ofdifferent drugs in the human placenta (30-32), but unfortunately to date, most of these studies were done using drugs not usually administered for cancer treatment. However, they can serve as a model for the assessment of cancer AC transfer and thus add important information regarding its safety during pregnancy.
EMBRYOFETAL EFFECTS IN THE FIRST TRIMENSTER
Chemotherapy increases the risk of abortion and congenital abnormalities when given in the first trimester. If AC is urgently required, induction of abortion might then be an option to discuss.
Studies on the teratogenicity of AC are usually based on animal models. However, the AC doses used in humans are often lower than the minimum teratogenic doses applied in animals. Therefore, it is difficult to extrapolate data from animal models to humans. The teratogenicity of ACis not only related to the kind of drug. It depends on interaction of several other factors, including, combination, time of exposure, dose, protein binding, and placental transfeÃ lkylating agents, antimetabolites, folate antagonists, purine or pyrimidine analogues used during organogenesis result in the highest risk of congenital malformations: around 6-17% with the use of a single agent and 15-25% with combination therapy (33-35).
A study on 139 cases of first trimester exposure to AC demonstrated a 17% risk for malformations after single-agent exposure and 25% after combination drugs exposure (36) . When folate antagonists were excluded, the incidence of fetal malformations with single-agent AC during the first trimester declined to 6% (37) . Therapy given in the first two weeks of pregnancy, before fetal circulation and organ development has been established, will generally have an "all or nothing" effect on the pregnancy: abortion or apparently no congenital abnormalities. On the other hand, the fetus is extremely vulnerable during weeks 2-8, when organogenesis occurs (10) .
If multidrug treatment in the first trimester is required, anthracyclines, vinca alkaloids, or single-agent treatment followed by multi-agent therapy after 12 weeks should be considered. Drugs like melphalan and procarbazine should not be used. Most experts recommend against the use of methotrexate in pregnancy unless no acceptable alternative exists because it has a dose-and trimester-dependent effect (38) . In the first trimester, it is an abortificant often used in the treatment of ectopic pregnancy. High doses of methotrexate are associated with the aminopterin syndrome (i.e., cranial dysotosis, delayed ossification, hypertelorism, wide nasal bridge micrognatia, and ear anomalies) (39) .
Methotrexate-containing regimens, such as Hyper CVAD, carry a high risk ofteratogenicity when used during the first trimester and profound fetal myelosuppression when used during the second or third trimester (40) .
All-trans retinoic acid (ATRA) given in the first trimester carries an 85% risk of teratogenicity, including severe neurological and cardiovascular complications, and together with chemotherapy is associated with an increased rate of miscarriage. ATRA, alone and in combination, given in the second and third trimesters has generally shown favorable outcomes in the mother and fetus, with 29 cases reported (41) (42) (43) (44) .
A review of 93 fetuses exposed during the first trimester to cytarabine alone or in combination with other chemotherapeutic agents, showed four cases of limb malformations (10) .
Fifteen out of 125 women exposed to imatinib during pregnancy had congenital abnormalities (45) .
There have been forty cases of interferon use in pregnancy, including eight cases offirst trimester use. The only case of fetal malformations was seen when interferon was used concurrently with hydroxyurea (46) (47) (48) (49) . Hydroxyurea, an antineoplastic drug that inhibits DNA synthesis, is a small molecule capable of crossing the placenta. Its use in pregnancy has been documented in 54 cases during various trimesters: 8 patients terminated pregnancy, 42 live births. (10 premature, 1 IUGR, 1 preeclampsia, and 1 IUGR with multiple anomalies), and 4 uterine demises (50).
The largest study looking at 31 cases from a single institution noted an increased risk of IUGR, uterine demise, and prematurity, but felt these complications may have also been due to the underlying disease they were used to treat (51).
Unlike chemotherapy, the risk associated with trastuzumab does not appear to be associated with early 1st trimester exposure. In studies of patients unintentionally exposed to trastuzumab during the first trimester, no congenital anomalies were encountered. This could be due to the transplacental transport of IgG which is very low in early pregnancy and it increases gradually starting the second trimester to reach a concentration similar to that of the mother by the end of gestation (52).
FETAL EFFECTS IN THE SECOND AND THIRD TRIMENSTER
Obstetrical outcomes of the children of women who received AC during the second or third trimester are generally good. After the first trimester, the risk of congenital malformations from chemotherapy is about 3%, which approaches the baseline population risk (53). Thus treatment after the first trimester, when structural development is largely complete, is reasonably safe and more appropriate than postponement of treatment for several weeks or months, until a mature infant can be delivered (36) .
AC effects on pregnancy after the first trimester could also include low birth weight, intrauterine growth restriction (IUGR), premature birth, stillborn fetus, impaired functional development, myocardial toxicity (54,55).
Second and third trimester chemotherapy exposure predisposes to placental underdevelopment and to the risk for intrauterine growth retardation (IUGR) and low birth weight (29,56)
A review of 376 cases of fetuses exposed prenatally to AC, most after organogenesis, has demonstrated 6% of fetal or neonatal death, 7% of IUGR, 5% of premature delivery and 4% oftransient myelosuppression (10) . When chemotherapy is administered shortly before delivery the newborn shows a transient myelosuppression (55) .
Although the risks of AC remain low, after the completion of the 12th week of gestation, it is important to note that eyes, genitalia, hematopoietic system and central nervous system remain vulnerable to continued drug exposure, with the possibility of mild dysfunction during infancy and adulthood (56,57).
Moreover, preterm birth, growth restriction and congenital malformations are not significantly different between newborns of women who have received chemotherapy during pregnancy and the control group (58, 59).
When fetuses were exposed in the second and third trimester to cytarabine , transient cytopenias were reported in 5 cases, intrauterine fetal death in 6 cases, IUGR in 12 cases, and neonatal death from sepsis and gastroenteritis in 2 cases (10) .
Daunorubicin is the anthracycline of choice in pregnancy, although three cases of fetal cardiac toxicity have been documented (37, 60) .
Prolonged exposure to trastuzumab, for more than one trimester, is the key risk factor behind the development of oligohydramnios. Seven out of 8 patients who developed oligohydramnios were exposed to trastuzumab for more than one trimester. However, the risk appeared to be much lower (1/7 cases) in those exposed to trastuzumab for one trimester or less (61) .
OBSTETRIC MONITORING AND DELIVERY MANAGEMENT
Evidence based guidelines on how to best monitor pregnancies exposed to AC are not currently available. The additional blood examinations and prenatal ultrasound exams, like morphometric and biometric ultrasound and umbilical artery Doppler, should be better chosen according to the specific mother and fetus needs. Antenatal exams should generally be performed with more accuracy and at shorter intervals in pregnancies exposed to AC, compared to non exposed prenacies with routine antenatal care (62). Blood analyses that should be more frequently assessed are hemoglobin concentration, white blood cells counts, platelets, creatinine and urine, liver function tests. Maternal weight and arterial blood pressure should be evaluated at each obstetric consultation. Nausea and vomiting in early pregnancy are very common and can be very distressing for cancer women. They could be due to the gestation, the cancer and/or the treatment. Many treatments are available to women with "morning sickness", including drugs and complementary and alternative therapies. Unfortunately there is a lack of high-quality evidence to support that advice as a cochrane review concluded (63).
For the well being of the fetus, all efforts should be made to delay delivery until week 35-37 of gestation. Early deliver may be associated with a worse neonatal outcome, depending on gestational age. Intra uterine growth retardation (IUGR) and low birth weight are mainly attributed to premature delivery that must be prevented. Timing of delivery is thus a critical issue. In chemotherapy-exposed pregnancies, the rate of pre-term delivery is in the range of 5-13% (64) . A pre-term birth is defined as delivery before the completion of week 37 of gestation (65). Very early pre-term birth is gestational age at birth ofless than 32 weeks while late pre-term birth is gestational age at birth of 32-36 weeks. In the general population, the rate of pre-term delivery is 12-13% in the United States and 5-9% in Europe (66). Data on premature babies (delivered before the 34th week of pregnancy) report a higher incidence of pulmonary and neurological toxicity, with the highest morbidity associated to very early delivery and low neonatal weight (67) . Even the so called "late preterm babies", delivered between the 34th and 37th week of pregnancy may suffer from long-term morbidity. Compared with infants born at term (at> 37 gestational weeks), late pre-term infants have higher rates of temperature instability, respiratory distress, apnea, hypoglycemia, seizures, jaundice, feeding difficulties, periventricular leukomalacia, and re-hospitalizations. They are also associated with a higher risk of developing long-term effects, such as difficulties in motor skills, speaking, writing, mathematics, and behavior (68) . The timing and the way of delivery should be chosen according to gestational age, maternal and fetal conditions, and type of tumor. In each case a thorough balance of the potential benefits and risks for both the mother and the fetus should be done. A wise balance between delivery anticipation with chemotherapy postponement or immediate administration of chemotherapy should be assessed for each case. Early administration of chemotherapy is associated with improved outcomes (69) .
The delay of chemotherapy until fetal maturity is arguable, unless delivery can be safely induced in few weeks. Possibly, delivery should be delayed by twothree weeks after AC to avoid the risk of bleeding and infection due to myelosuppression after chemotherapy. Chemotherapy should not be given after 34-35 weeks of gestation as spontaneous delivery can occur before bone marrow recovery. The delay of delivery for 2-3 weeks after chemotherapy, depending on the regimen used, also allows for fetal drug excretion via the placenta. Chemotherapy administered shortly before delivery might not be eliminated from the fetus before delivery, and thus may persist in the newborn. This is especially true for pre-term babies, who have a limited ability to metabolize drugs due to liver and kidney immaturity. If chemotherapy is planned to be continued following delivery, the first dose should be given following adequate recovery.
The choice between vaginal delivery and caesarean section should be individualized. Vaginal delivery should be preferred, if not contraindicated, in most of the cancer patients. It may also be less likely to delay initiation or restart of chemotherapy due to lower morbidity compared with cesarean section. The differences in neonatal physiology following vaginal and caesarean births are thought to have implications for the infant, with caesarean section potentially increasing the risk of compromised health in both the short and the long term.
The potential benefits of planned caesarean section include greater safety for the baby, less pelvic floor trauma for the mother, avoidance of labor pain and convenience. The major potential disadvantages include increased risk of major morbidity or mortality for the mother. Further disadvantages like the problems in subsequent pregnancies, including uterine scar rupture and a greater risk of stillbirth and neonatal morbidity, are a lesser problem in cancer patients. In recent years, caesareans have become safer due to improved anesthesia and improved surgical techniques, along with the routine use of drugs at surgery to combat the increased risk of infection and blood clots in the mother. However, caesarean section remains a surgical procedure accompanied by risks, abdominal and uterine incisions, scarring and adhesions. There is no evidence from randomized controlled trials, upon which to base any practice recommendations, so an unbiased assessment of advantages and disadvantages should be extensively discussed with each patient (70) .
Cervical cancer patients diagnosed during pregnancy are usually advised to deliver by cesarean section, as episiotomy scar recurrences after vaginal delivery have been described (71) . Although obstetrical outcomes of newborns with antenatal exposure to chemotherapy are good and the risk of vertical transmission of metastases from maternal cancer is low, accurate clinical follow up is required.
Occasionally ovarian malignancies 0 pelvic metastases are incidentally diagnosed during cesarean section (72) .
Fetal metastases from maternal malignancies represent a rare event and when it occurs the prognosis is very poor.
The mechanism of transplacental metastases from maternal cancers is not clear and poorly understood.
Current opinions reveal that fetus has a tolerance for maternal antigens and it is unable to recognize as 'not-self' maternal cells prior to the development of immunologic competence (6) . Placenta is very vascular and produces growth factors and endothelial adhesion molecules that may facilitate adhesion, survival and invasion of neoplastic cells (73) .
In a comprehensive literature review, Alexander et al. (74) found that, since 1866, only 87 cases of placental or fetal metastases have been reported. Melanoma is the neoplasm that most frequently involves placenta or fetus accounting for 27 of87 (31%) cases. Out of the 27 cases, 6 fetal metastases occurred, with 5 of these 6 infants succumbing to metastatic disease (74) .
The prevalence of melanoma metastases to the fetus is probably due to the reduced HLA class I and II exposure on the cell surface, thus reducing the fetus ability to recognize the tumor cells as foreign. Moreover, estrogen and progesterone receptors are usually absent in pregnancy associated melanoma (75, 76) and placental and vascular endothelial growth factors stimulate melanoma cells growth in vitro (77, 78) .
Placental and fetal metastases are always associated to hematogenous dissemination of metastatic maternal malignancy. Although placental involvement is rare and not certainly associated to fetal metastases, it is necessary to be recognized because only in case of neoplastic spread to placenta fetal metastases may occur (79) Placental metastases may be not detected to macroscopic and conventional histologic examination, because placental involvement is not always characterized by large evident metastatic lesions, and fetal transmission may occur also in case of placental micro metastases (16) . For these reasons, in case of maternal malignancies occurring during pregnancy, histological examination of the placenta with semi-sequential sections and using immunohistochemycal techniques to detect also micro metastases is mandatory to exclude vertical transmission of cancer to the fetus.
POST NATAL AND LONG TERM EFFECTS
Antiblastic chemotherapy tOXICItIes such as anemia, neutropenia, pancytopenia, and alopecia have been observed in newborns of mother treated during pregnancies (10) . The delay of three weeks after maternal chemotherapy decreases but does not rule out completely the child's risk of bone marrow suppression at birth. Most of the reported neonatal complications are related to anticipated delivery and include breathing difficulties, and subarachnoid hemorrhage (80) .
Infants suffering respiratory distress after delivery could take several months after delivery to recover (81-84).
Postnatal consequences depend not only on AC effects but also on perinatal care. In a single institution experience one baby was exposed to chemotherapy during all the trimesters and was born prematurely and later died because of intracranial bleeding. Four babies were exposed to chemotherapy during the first trimester, one of them had low birth weight and floating thumb malformation, two of them had only low birth weight, and one was born healthy, but died at 3 months of age as a result of severe gastroenteritis. Two babies were exposed to chemotherapy during the second and third trimesters; one of them had low birth weight, and the other pregnancy ended in uterus death. One infant was exposed to chemotherapy during the third trimester and was born at term, but died because of pulmonary hemorrhage (85).
Antineoplastic agents administered systemically might reach clinically significant levels in breast milk, so breastfeeding is contraindicated (55, 86) .
There are apparently no significant long-term effects on the children exposed to AC in-uterus compared to the normal population, but the issue is still controversial. Earlier studies have shown that late manifestations of in uterus exposure to chemotherapeutic agents may rarely include impaired growth and possibly diminish neurologic and/or intellectual function (87,88).
Subsequent longer follow-up and review of existing data have shown that chemotherapy does not have an effect on late neurodevelopment, fertility, or future malignancies in the exposed fetus (89). Furthermore, a large study investigated the effects ofAC on 84 children with a mean follow-up of 18.7 years. The study found no physical, neurological, or psychological abnormalities, and normal cognitive development. In addition, no childhood cancer was reported in the first-or second-generation children (40) .
The very limited available information does not suggest that children born to mothers treated with chemotherapy during pregnancy have impaired mental or physical development or will be infertile. Among 43 children whose mothers were treated with AC, including 20 treated during the first trimester, there were no instances of congenital malformation. All the children had normal physical and cognitive function when examined between 3 and 19 years of age (90).
In the MD Anderson study, follow-up until school age was conducted for 18 of the newborns showing normal development (37) .
In a prospective study using weekly epirubicin (91) all newborns were normal at a median follow-up period of 2 years following delivery.
A pediatric study of 93 babies born after pregnancy AC, at a mean age of41.8 months. Mean weight and height percentiles were 48% and 58% respectively. Medical issues included gastro esophageal reflux, pneumonia, corneal abrasion, IgA deficiency, otitis media, and speech delays in 2 cases exposed to chemotherapy in uterus. Long term medical issues affecting children not exposed to chemotherapy included speech delay in one case and neurofibromatosis in another (92) .
A study examining the relationship between gestational age at birth and outcomes in adulthood showed that the risks of medical and social disabilities in adulthood increase with decreasing gestational age at birth (93, 94) . Thus, every possible effort should be made to avoid preterm delivery. Currently data suggest that antenatal exposure to AC is not associated with poorer cardiac and neurodevelopmental outcomes or with impairments to general health and growth compared with general population. In an interim analysis of a multicentre observational cohort study assessing children who were prenatally exposed to maternal cancer staging and treatment, including chemotherapy (95) 236 cycles of chemotherapy were administered in 68 pregnancies. Seventy children, born at a median gestational age of 35.7 weeks, with a median follow-up period of 22.3 months were assessed. Although neurocognitive outcomes were within normal ranges, cognitive development scores were lower for children who were born preterm than for those born at full term. When controlling for age, sex, and country, the score for IQ increased by an average l1.6 points (95% CI 6,0-17'1) for each additional month of gestation (p<0'000 1). Prematurity was common and was associated with impaired cognitive development. Therefore, iatrogenic preterm delivery should be avoided when possible ant the subtle changes in cardiac and neurocognitive measurements emphasize the need for longer follow-up.
The risk of secondary malignant disease after in uterus exposure to chemotherapy is unknown. No cases have been reported of secondary leukemia in exposed fetuses.
More information is needed with regard to subsequent gonadal function and the risk ofcancer among children who were exposed to chemotherapeutic agents in uterus, but the existing data suggest that if aggressive chemotherapy after the first trimester will improve maternal outcome, physicians should not be reluctant to use it.
ACs are DNA-damaging treatments that can also result in genetic damage being transmitted to the offspring, via a mutated germ cell and transgenerational instability in the germ line. Determining whether AC imparts genetic risks to the future children of cancer survivors is challenging (96) .
ANTIBLASTIC CHEMOTHERAPY IN PREGNACY: ISSUES RELEVANT FOR COUNSELLING OF THE MAIN CANCERS BREAST
Breast cancer is the most common malignancy associated with pregnancy after cervical carcinoma with an estimated incidence of about 1 in 3000 pregnancies. Up to 0.2-3.8% ofbreast cancers coincide with pregnancy.
Indications for AC during pregnancy should not be different from those outside pregnancy and should depend upon the patient disease stage and tumor biology.
Physicians should consider administration of AC starting from the completion of the 12th week of gestation. In the adjuvant setting different anthracycline-based regimens are described (62, 97).
Tamoxifen is contraindicated in pregnancy due to several studies reporting malformations, mainly craniofacial anomalies, ambiguous genitalia and Goldenhar's syndrome. Aromatase inhibitors are contraindicated as a single-agent endocrine therapy in premenopausal women (98) .
Trastuzumab is reported to cause a reduction in the amniotic fluid volume in pregnant women (oligohydramnios or anhydramnios) which is known to significantly increase the risk of premature delivery, fetal morbidity and mortality. However, current clinical evidence relies on 15 published case-reports only (99) .
Intra uterine exposure to bisphosphonates for the treatment of bone metastases can increase risk of fetal skeletal anomalies. These drugs also cause hypocalcaemia which could affect uterine contraction and should be better administered following delivery, whenever possible (100).
CERVIX
Cervical carcinomas are the second most frequent cancer in pregnant patients: one third ofall occur during the reproductive period. Neoadjuvant AC based on cisplatin should be used during the second trimester of pregnancy in order to make it possible to wait for fetal pulmonary maturity, with definitive treatment applied after delivery. This approach seems to be feasible and relatively safe for the fetus (101, 102) .
Advanced cervical carcinoma rarely occurs during pregnancy. However an immediate treatment with cisplatin-based AC followed by RT is the treatment of choice. For diagnoses made during the second trimester of pregnancy or better when pulmonary maturation is achieved a caesarean section is the first option followed by AC-RT (103, 104) .
MELANOMA
Malignant melanoma is one of the most common types of cancer that occurs among women during their childbearing years. Prognosis of pregnancy associated melanoma is not different from that ofmelanoma occurring outside pregnancy (105, 106) .
Melanoma is the most common type of malignancy to metastasize to the placenta and fetus, representing 30% of placental metastases and 58% of fetal metastases. A careful microscopic examination of the placenta with known metastatic melanoma should be recommended as well as close observation and follow-up of the infant (107) (108) (109) .
The use of adjuvant immune therapy with interferon is an accepted treatment option and available data suggest that its use does not increase significantly the incidence of fetal malformations or abortion when used during pregnancy (110) .
The use of AC in a pregnant woman affected by metastatic melanoma is a challenging situation due mainly to its palliative value with the absence of significant increase in survival and the potential adverse events on the fetus.
AC agents with activity in patients with metastatic melanoma include single-agent dacarbazine and combinations (such as tamoxifen, carmustine, dacarbazine and cisplatin or tamoxifen, nimustine, cisplatin and dacarbazine). Generally, AC should be offered in the presence of a symptomatic metastatic disease and with the intent to carry the pregnancy to delivery (Ill, 112). Hematologic malignancies represent 25% of cancers affecting pregnancy and their incidence ranges from 1 in 1000 to 1 in 10000 deliveries (113) .
Hodgkin's lymphoma is the most common lymphoma diagnosed during pregnancy. The combination of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD regimen) is the most widely used and has been described in patients diagnosed during pregnancy. To date, more than 30 patients have been reported to be treated with ABVD (3) . When considering patients who were treated after the first trimester, the regimen was not associated with adverse maternal or fetal toxicities. ABVD has been shown safe and effective at any gestational time and at any stage of disease. In only one case, intrauterine fetal death (IUFD) was reported (114) .
NON-HODGKIN LYMPHOMA
Aggressive non-Hodgkin's lymphomas are less common in the young population, however, several cases have been reported and treated during the course of gestation. The current standard of care is the CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) regimen with the addition of the monoclonal antibody rituximab in patients with B-cell lymphomas. Similar to the results obtained by ABVD, the regimen was generally well tolerated with no specific fetal or maternal adverse events. In one case, a preterm infant was delivered preterm and had transient leucopenia, which resolved later (115) .
Rituximab use is safe in pregnancy, even during the first trimester, and only transient B-cell depletion has been reported in neonates exposed to rituximab, which is followed by full immunological recovery and normal response to vaccines (61, (116) (117) (118) (119) . Rituximab therapy is a viable option for deferring cytotoxic therapy early during pregnancy and might help to reduce the risk of abortion, fetal malformation, developmental retardation or immune dysfunction in the child while producing a complete remission in the mother. These findings not only demonstrate an uneventful clinical course after rituximab administration during pregnancy but also show that recovery from intrauterine B-cell depletion can be fast with no obvious long-term effects (120) . Rituximab is a large molecule and hence transplacental crossing requires an active transport mechanism which is activated starting the second trimester (52). Hence, unlike chemotherapy, early exposure (i.e. during the l st trimester) is unlikely to be associated with a high risk of congenital malformations but prolonged exposure later on could potentially be associated with fetal toxicities. Minor fetal toxicities were reported secondary to the administration of rituximab during gestation. This was limited to B-cell depletion at birth which was generally reversible within few months (121) . Data on rituximab is limited to less than 10 cases in the literature (61) . Use of CHOP does not seem to affect fetal development when used during the first trimester (122, 123) .
LEUKEMIA
Acute leukemias affect an estimated one every 10,000 pregnancies (11) . They are generally aggressive and require immediate initiation of therapy once diagnosed. Acute myeloid leukemia is the most common leukemia during pregnancy and it is virtually the only condition requiring immediate chemotherapy in a pregnant woman. Combinations of vincristine, doxorubicin, daunorubicin, idarubicin, cytarabine, cyclophosphamide, asparaginase, mercaptopurine, prednisone, methotrexate, mitoxantrone, and all-trans-retinoic acid (ATRA) have been used during all trimesters. A review of 152 patients with ALL (63 cases) and AML (89 cases) found six (4%) neonates with congenital abnormalities, 12 (8%) with IUGR, 11 (7%) fetal demises, and 2 (1%) neonatal deaths (10) .
Strikingly was the relatively high rate of complications observed secondary to administration of daunorubicin and idarubicin during pregnancy. This was observed even in patients treated following the first trimester. Respiratory distress syndrome, IUFD, intrauterine growth retardation was all reported in addition to congenital anomalies including limb deformities, and ventral septal defect (81, 124, 125) .
Similar results were also obtained when the same regimens were administered in patients with acute lymphoblastic leukemia (126) . Both agents are more lipophilic compared to other anthracyclines and this could result in more transplacental transfer and fetal toxicity. An alternative in this case could be doxorubicin in which available evidence support adequate clinical activity (127) . Current evidence strongly favors avoiding both agents during pregnancy.
Acute promyelocytic leukemia is relatively uncommon and is characterized by the presence of a specific chromosomal translocation (15/17), which is targeted by all trans retinoic acid (ATRA). To the best of our knowledge, no reports have been published on serious fetal complications when ATRA was given as single agent during pregnancy. Complications were mainly reported when the drug was given in combination with daunorubicin or idarubicin based chemotherapy Chronic leukemia is relatively rare in women during the childbearing period. Among them, chronic myeloid leukemia is the most common and has been described during pregnancy. Imatinib, which targeted the BCRJABL fusion gene, is associated with very high rates of complete remissions. Unlike chemotherapy, this agent does not cause amenorrhea. Hence several reports have been published on accidental pregnancies during the treatment course, resulting in high rates of spontaneous abortions. Administration of the drug following the first trimester was generally well tolerated (45) . The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) is the recommended treatment in the second and third trimester, as the majority of NHL in pregnancy is DLBCL (128) (129) (130) (131) (132) (133) .
COLORECTAL
The incidence of CRC during gestation appears to be I in 13,000 pregnancies (134). 5-fluorouracil (5-FU), the most commonly used AC agent for the treatment of CRC, could potentially cause fetal abnormalities by affecting fetal DNA synthesis and cell development through inhibition of embryonic thymidylate synthetase (135) . Moreover, 5-FU crosses the placenta and enters fetal circulation in the rat and causes fetal toxicity in several laboratory animals (i.e. rats, monkeys). Limited data have been published on fetal safety in humans and 5-FU seems to be safe for the fetus particularly during second and third trimester. Oxaliplatin has not been studied in pregnant women. However, studies in animals have shown that oxaliplatin causes miscarriages, decreased weight or death to the fetus, and problems with bone formation. Irinotecan may cause harm to the fetus when given during pregnancy. No human data are available. Bevacizumab has not been studied in pregnant women. Studies on the effect of cetuximab in pregnancy have not been performed in humans or animals (136) .
CONCLUSION
Cancer occurring in pregnancy represents a challenge for patients, her family and physicians. It is a very critical clinical situation and presents three fundamental issues to consider, summarized in table I: oncological, obstetrical and ethical, religious, psychologic and medico legal . Use of antiblastic chemotherapy (AC) during pregnancy is a very complex and risky choice that needs a special counseling strategy.
Ethical considerations and the relative rarity of the disease limit the possibility to perform large randomized trials and, until now, definitive treatment guidelines are lacking. For these reasons, patients have to be extensively counseled and informed that scientific evidence is scarce, but not absent. Patient's autonomy is crucial for the decision of maintenance pregnancy, and physician's moral judgment should not influence it.
Multidisciplinary approach is mandatory requiring continuous cooperation between oncologists, obstetrics, pathologists and pediatrics both for counseling of the patient and for clinical management. A psychologist is also needed because of the strong emotional factors involved. According to specific situations other specialists involved like radiologist, genetist, neonatologist and anesthesiologist.
The standard doses of drugs are recommended in pregnancy, but studies are lacking and drug metabolism is changed. Chemotherapy should mimic that of no pregnant patients as much as possible, taking into consideration the gestational age at presentation and the specific disease. Administration of AC during the first trimester should be avoided being associated with a high risk of malformations. In case initiation of therapy is urgently required during the first trimester induction of abortion is an option to discuss.
Long-term follow-up of offspring exposed to chemotherapy is needed, especially regarding neurocognitive development, secondary malignancies and fertility. Due to the relative rarity of pregnancyassociated cancer, only few medical centers or physicians have gained an expertise in this field. Therefore, there is a critical need for multi-center cooperation and a central registry that will collect and follow a large number of cases of pregnancy-associated cancer. This will facilitate conducting better epidemiologic studies and improved long-term follow-up that will enable physicians to more accurately counsel and manage pregnant cancer patients.
